Antiblastic  ||| S:0 E:12 ||| JJ
treatment  ||| S:12 E:22 ||| NN
of  ||| S:22 E:25 ||| IN
haematological  ||| S:25 E:40 ||| JJ
malignancies  ||| S:40 E:53 ||| NN
during  ||| S:53 E:60 ||| IN
pregnancy ||| S:60 E:69 ||| NN
:  ||| S:69 E:71 ||| :
a  ||| S:71 E:73 ||| DT
crucial  ||| S:73 E:81 ||| JJ
decision  ||| S:81 E:90 ||| NN
Antiblastic  ||| S:90 E:102 ||| NNP
treatment  ||| S:102 E:112 ||| NN
of  ||| S:112 E:115 ||| IN
hematological  ||| S:115 E:129 ||| JJ
malignancies  ||| S:129 E:142 ||| NN
during  ||| S:142 E:149 ||| IN
pregnancy  ||| S:149 E:159 ||| NN
poses  ||| S:159 E:165 ||| VBZ
a  ||| S:165 E:167 ||| DT
number  ||| S:167 E:174 ||| NN
of  ||| S:174 E:177 ||| IN
issues  ||| S:177 E:184 ||| NNS
related  ||| S:184 E:192 ||| VBN
to  ||| S:192 E:195 ||| TO
the  ||| S:195 E:199 ||| DT
curability  ||| S:199 E:210 ||| NN
of  ||| S:210 E:213 ||| IN
the  ||| S:213 E:217 ||| DT
maternal  ||| S:217 E:226 ||| JJ
disease ||| S:226 E:233 ||| NN
,  ||| S:233 E:235 ||| ,
the  ||| S:235 E:239 ||| DT
need  ||| S:239 E:244 ||| NN
of  ||| S:244 E:247 ||| IN
a  ||| S:247 E:249 ||| DT
prompt  ||| S:249 E:256 ||| JJ
treatment  ||| S:256 E:266 ||| NN
and  ||| S:266 E:270 ||| CC
the  ||| S:270 E:274 ||| DT
potential  ||| S:274 E:284 ||| JJ
toxicity  ||| S:284 E:293 ||| NN
of  ||| S:293 E:296 ||| IN
chemotherapy  ||| S:296 E:309 ||| NN
for  ||| S:309 E:313 ||| IN
the  ||| S:313 E:317 ||| DT
fetus ||| S:317 E:322 ||| NN
.  ||| S:322 E:324 ||| .
Here  ||| S:324 E:329 ||| RB
we  ||| S:329 E:332 ||| PRP
report  ||| S:332 E:339 ||| VBP
the  ||| S:339 E:343 ||| DT
results  ||| S:343 E:351 ||| NNS
of  ||| S:351 E:354 ||| IN
a  ||| S:354 E:356 ||| DT
systematic  ||| S:356 E:367 ||| JJ
literature  ||| S:367 E:378 ||| NN
search  ||| S:378 E:385 ||| NN
about  ||| S:385 E:391 ||| IN
the  ||| S:391 E:395 ||| DT
management  ||| S:395 E:406 ||| NN
of  ||| S:406 E:409 ||| IN
the  ||| S:409 E:413 ||| DT
most  ||| S:413 E:418 ||| RBS
frequent  ||| S:418 E:427 ||| JJ
hematological  ||| S:427 E:441 ||| JJ
malignancies  ||| S:441 E:454 ||| NN
that  ||| S:454 E:459 ||| WDT
may  ||| S:459 E:463 ||| MD
occur  ||| S:463 E:469 ||| VB
during  ||| S:469 E:476 ||| IN
pregnancy ||| S:476 E:485 ||| NN
,  ||| S:485 E:487 ||| ,
focusing  ||| S:487 E:496 ||| VBG
on  ||| S:496 E:499 ||| IN
specific  ||| S:499 E:508 ||| JJ
issues  ||| S:508 E:515 ||| NNS
related  ||| S:515 E:523 ||| VBN
to  ||| S:523 E:526 ||| TO
gestational  ||| S:526 E:538 ||| VB
age  ||| S:538 E:542 ||| NN
at  ||| S:542 E:545 ||| IN
diagnosis ||| S:545 E:554 ||| NN
,  ||| S:554 E:556 ||| ,
fetal  ||| S:556 E:562 ||| JJ
toxicity  ||| S:562 E:571 ||| NN
and  ||| S:571 E:575 ||| CC
efficacy  ||| S:575 E:584 ||| NN
on  ||| S:584 E:587 ||| IN
the  ||| S:587 E:591 ||| DT
maternal  ||| S:591 E:600 ||| JJ
side ||| S:600 E:604 ||| NN
.  ||| S:604 E:606 ||| .
The  ||| S:606 E:610 ||| DT
standard  ||| S:610 E:619 ||| JJ
approach  ||| S:619 E:628 ||| NN
in  ||| S:628 E:631 ||| IN
non-pregnant  ||| S:631 E:644 ||| JJ
women  ||| S:644 E:650 ||| NNS
is  ||| S:650 E:653 ||| VBZ
illustrated  ||| S:653 E:665 ||| VBN
as  ||| S:665 E:668 ||| IN
reference ||| S:668 E:677 ||| NN
.  ||| S:677 E:679 ||| .
